Safety And Efficacy Of Exubera Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents

This study has been terminated.
(See termination reason in detailed description.)
Information provided by:
Pfizer Identifier:
First received: May 24, 2007
Last updated: October 31, 2008
Last verified: October 2008
To assess the safety and efficacy of Exubera on pulmonary function and glycemic control in subjects ages 6-17 over a 1 year period.

Condition Intervention Phase
Diabetes Mellitus, Type 1
Drug: Inhaled insulin (Exubera)
Drug: Subcutaneous Insulin (subject's prescribed)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Safety And Efficacy Of Exubera® (Inhaled Insulin) Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents Ages 6-17 Years With Type 1 Diabetes Mellitus: A 12 Month, Outpatient, Randomized, Open Label, Parallel Group Comparative Trial.

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • To Assess Pulmonary Safety and Glycemic Control of Exubera Over a 12 Month Controlled Period [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Change From Baseline in Other PFT Parameters [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • Slope From Baseline to Week 52 and Slope From Week 12 to Week 52 for FEV1 and FVC as a Percent of Predicted; [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • Change From Baseline in FVC [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • Proportion of Subjects Achieving ADA Age Appropriate Guidelines for HbA1c [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Change From Baseline in Body Weight (kg), Height (cm), and Body Mass Index (BMI; kg/m2) and z Score (%);Dose of Insulin; [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Hypoglycemic Event Rates; [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • Treatment Preferences. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Slope for Other PFT Parameters; [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • Change From Baseline in Insulin Antibodies (microU/mL); [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • 7 Point Home Glucose [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 554
Study Start Date: October 2007
Study Completion Date: October 2007
Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Inhaled insulin (Exubera) Drug: Inhaled insulin (Exubera)
Inhaled insulin with dose adjusted according to premeal blood glucose
Active Comparator: Subcutaneous Insulin (subject's prescribed) Drug: Subcutaneous Insulin (subject's prescribed)
Subcutaneous insulin with dose adjusted according to premeal blood glucose

Detailed Description:
Pfizer announced in October 2007 that it would stop marketing Exubera. At that time recruitment for the pediatric study, A2171083, was placed on hold. Two subjects completed the informed consent/assent process and entered the A2171083 study but none received treatment. The first subject withdrew consent during the Baseline Run-in period which was prior to Randomization. The second subject screen failed at Visit 1. After this time, Nektar, the company from which Pfizer licensed Exubera, announced on April 9, 2008 that it had stopped its search for a new marketing partner. Accordingly, there will be no commercial availability of Exubera. As a result, study A2171083 was terminated and no further recruitment took place.

Ages Eligible for Study:   6 Years to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects with Type 1 diabetes mellitus for more than 6 months.
  • Males and females ages 6 to 17 years.
  • Subjects should be receiving, or be able to tolerate, at a minimum a 3 unit pre prandial dose of short acting subcutaneous insulin.

Exclusion Criteria:

  • Subjects using an insulin pump
  • Smoking
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00479258

United States, New York
Pfizer Investigational Site
Buffalo, New York, United States, 14222
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc. Identifier: NCT00479258     History of Changes
Other Study ID Numbers: A2171083 
Study First Received: May 24, 2007
Results First Received: October 29, 2008
Last Updated: October 31, 2008
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Autoimmune Diseases
Endocrine System Diseases
Glucose Metabolism Disorders
Immune System Diseases
Metabolic Diseases
Insulin, Globin Zinc
Hypoglycemic Agents
Pharmacologic Actions
Physiological Effects of Drugs processed this record on April 27, 2016